Quinazoline Derivatives for Selective TLR8 Agonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel Toll-Like Receptor (TLR) modulators with improved selectivity and safety profiles, particularly for TLR8 agonism, to effectively treat viral infections and inflammatory disorders without causing systemic immune overstimulation.
Innovation Solution
Development of quinazoline derivatives with specific structural modifications that exhibit enhanced TLR8 agonism while minimizing TLR7 activation, potentially used in pharmaceutical compositions to stimulate a Th1 immune response and cytokine production, such as IL-12, for treating viral infections and cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TLR7/8 agonists are used to induce cytokines, then immune response is enhanced, but systemic immune overstimulation occurs
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular characteristics that selectively interact with TLR8 rather than TLR7. The quinazoline core structure with specific substituent patterns (R1-R5 groups) creates a ligand that fits the TLR8 binding pocket geometry and chemical environment, producing localized immune activation at the TLR8 receptor site without triggering the broader systemic response associated with TLR7 activation.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the quinazoline derivatives, including substituent types (fluorine, hydroxyl, amino, nitrile, ester, amide groups), their positions (R1-R5), and stereochemistry ((R)-configuration at the carbon bonded to the amine). These parameter modifications tune the compound's affinity and selectivity for TLR8, enhancing desired immune response while minimizing harmful overstimulation.
2Object-affected harmful factors
If TLR8 selectivity is improved, then safety profile is enhanced, but compound design complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecule into distinct functional segments: the quinazoline core (providing basic TLR binding), the chiral amine side chain (with (R)-configuration for steric recognition), and various substituent groups (R1-R5) that fine-tune selectivity. This modular design allows systematic optimization of TLR8 selectivity while managing design complexity through structured variation of discrete segments.
Solution Approach 2:
The patent employs asymmetry through the specified (R)-configuration at the carbon atom bonded to the amine in the 4-position of the quinazoline. This chiral center creates an asymmetric molecular geometry that is recognized by the asymmetric binding site of TLR8, enhancing selectivity. The asymmetric design is complemented by non-symmetric substituent patterns at R1-R5 positions, further discriminating between TLR7 and TLR8 binding.
Data Source
AI summary
This application relates to quinazoline derivatives of formula (I), pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds of formula (I) in the treatment or prevention of a viral infection, of a virus-induced disease, of cancer or of an allergy. In formula (I), R1 is a C3-8alkyl, optionally substituted by one or more substituents independently selected from fluorine, hydroxyl, amino, nitrile, ester, amide, C1-3 alkyl, or C1-3 alkoxy, the carbon of R1 bonded to the amine in the 4-position of the quinazoline is in (R)-configuration, R2 is hydrogen, deuterium, fluorine, chlorine, methyl, methoxy, cyclopropyl, trifluoromethyl, or carboxylic amide, wherein each of methyl, methoxy and cyclopropyl is optionally substituted by one or more substituents independently selected from fluorine and nitrile, R3 is hydrogen or deuterium, R4 is hydrogen, deuterium, fluorine, methyl, carboxylic ester, carboxylic amide, nitrile, cyclopropyl, C4-7 heterocycle, or 5-membered heteroaryl group, wherein each of methyl, cyclopropyl, C4-7 heterocycle and 5-membered heteroaryl group is optionally substituted by one or more substituents independently selected from fluorine, hydroxyl, or methyl, R5 is hydrogen, deuterium, fluorine, chlorine, methyl, or methoxy, provided that at least one of R2, R3, R4 and R5 is not hydrogen.